• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Augmedix Inc. (Amendment)

    11/22/23 4:16:07 PM ET
    $AUGX
    Business Services
    Consumer Discretionary
    Get the next $AUGX alert in real time by email
    SC 13D/A 1 tm2331315d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES

    SECURITIES & EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 7)
    *

     

    Augmedix, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    05105P 107

     

    (CUSIP Number)

     

    Redmile Group, LLC

    Attn: Jennifer Ciresi

    One Letterman Drive, Bldg D, Ste D3-300
    San Francisco, CA 94129

    (415) 489-9980

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    November 20, 2023

     

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 13d-7(b) for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No.: 05105P 107

      

    1. NAME OF REPORTING PERSON
      Redmile Group, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
      (b) ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
      OO (1)
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      Delaware
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
      22,092,211 (2)
    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
      22,092,211 (2)
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      22,092,211 (2)
    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      40.7% (3)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      IA, OO
           

    (1) The source of funds was working capital of the Redmile Funds (as defined in footnote (2) below).

     

    (2) The aggregate amount of shares of common stock, $0.0001 par value per share, of the Issuer (the “Common Stock”) that may be deemed beneficially owned by the Reporting Person are held directly by certain private investment vehicles managed by Redmile Group, LLC (collectively, the “Redmile Funds”), including Redmile Private Investments II, L.P. and RedCo II Master Fund, L.P. Redmile Group, LLC (“Redmile”) is the investment manager/adviser to each Redmile Fund and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    (3) Percent of class calculated based on: (a) 48,555,216 shares of Common Stock outstanding as of November 20, 2023, as disclosed in the Issuer’s prospectus supplement filed with the SEC on November 17, 2023 (the “Prospectus Supplement”) and a Form 8-K filed with the SEC on November 20, 2023 (the “Form 8-K”), plus (b) 5,709,792 shares of Common Stock issuable upon the exercise of warrants held by certain of the Redmile Funds that are currently exercisable, including the Pre-Funded Warrants and Breakeven Warrant as described in Item 3 below.

     

     - 2 - 

     

    CUSIP No.: 05105P 107

     

    1. NAME OF REPORTING PERSON
      Jeremy C. Green
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
      (b) ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
      OO (1)
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      United Kingdom
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
      22,092,211 (2)
    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
      22,092,211 (2)
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      22,092,211 (2)
    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      40.7% (3)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      IN, HC
           

    (1) The source of funds was working capital of the Redmile Funds.

     

    (2) The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Person are held directly by the Redmile Funds, including Redmile Private Investments II, L.P. and RedCo II Master Fund, L.P. Redmile is the investment manager/adviser to each Redmile Fund and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    (3) Percent of class calculated based on: (a) 48,555,216 shares of Common Stock outstanding as of November 20, 2023, as disclosed in the Prospectus Supplement and the Form 8-K, plus (b) 5,709,792 shares of Common Stock issuable upon the exercise of warrants held by certain of the Redmile Funds that are currently exercisable, including the Pre-Funded Warrants and Breakeven Warrant as described in Item 3 below.

     

     - 3 - 

     

    CUSIP No.: 05105P 107

     

    1. NAME OF REPORTING PERSON
     

    Redmile Private Investments II, L.P.

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
      (b) ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
     

    WC

    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      Delaware
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
     

    7,135,652 (1)

    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
     

    7,135,652 (1)

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     

    7,135,652 (1)

    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      14.4% (2)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      PN
           

    (1) The aggregate amount of shares of Common Stock that is beneficially owned by the Reporting Person is comprised of 6,218,238 shares of Common Stock and a warrant to purchase 917,414 shares of Common Stock held by the Reporting Person.

     

    (2) Percent of class calculated based on: (a) 48,555,216 shares of Common Stock outstanding as of November 20, 2023, as disclosed in the Prospectus Supplement and the Form 8-K, plus (b) 917,414 shares of Common Stock issuable upon the exercise of a warrant that is currently exercisable.

     

     - 4 - 

     

    CUSIP No.: 05105P 107

     

    1. NAME OF REPORTING PERSON
      RedCo II Master Fund, L.P.

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ¨
      (b) ¨
    3. SEC USE ONLY
       
    4. SOURCE OF FUNDS (SEE INSTRUCTIONS)
     

    WC

    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
      ¨
    6. CITIZENSHIP OR PLACE OF ORGANIZATION
      Cayman Islands
    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH
    7. SOLE VOTING POWER
      0
    8. SHARED VOTING POWER
     

    13,665,140 (1)

    9. SOLE DISPOSITIVE POWER
      0
    10. SHARED DISPOSITIVE POWER
     

    13,665,140 (1)

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     

    13,665,140 (1)

    12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
      25.9% (2)
    14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      PN
           

    (1) The aggregate amount of shares of Common Stock that is beneficially owned by the Reporting Person is comprised of 9,446,146 shares of Common Stock, a warrant to purchase 3,125,195 shares of Common Stock and a Breakeven Warrant to acquire 1,093,799 shares of Common Stock held by the Reporting Person.

     

    (2) Percent of class calculated based on: (a) 48,555,216 shares of Common Stock outstanding as of November 20, 2023, as disclosed in the Issuer’s Prospectus Supplement and the Form 8-K, plus (b) 3,125,195 shares of Common Stock issuable upon the exercise of a Pre-Funded Warrant that is currently exercisable, plus (c) 1,093,799 shares of Common Stock issuable upon the exercise of a Breakeven Warrant that is currently exercisable.

     

     - 5 - 

     

     

    This amendment No. 7 to Schedule 13D amends and supplements the Schedule 13D filed with the SEC on October 15, 2020, as previously amended and supplemented by amendment No. 1 to the Schedule 13D filed with the SEC on March 1, 2021, amendment No. 2 to the Schedule 13D filed with the SEC on October 28, 2021, amendment No. 3 to the Schedule 13D filed with the SEC on September 2, 2022, amendment No. 4 to the Schedule 13D filed with the SEC on April 21, 2023, amendment No. 5 to the Schedule 13D filed with the SEC on May 4, 2023, and amendment No. 6 to the Schedule 13D filed with the SEC on June 15, 2023 (collectively, the “Prior Schedule 13D”), by Redmile Group, LLC (“Redmile”), Jeremy C. Green, and certain affiliates relating to the Common Stock of Augmedix, Inc., a Delaware corporation (the “Issuer”).

     

    Capitalized terms used but not defined in this amendment No. 7 shall have the meanings set forth in the Prior Schedule 13D. Except as specifically amended by this Amendment No. 7, the Prior Schedule 13D is unchanged.

     

    ITEM 3.Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Prior Schedule 13D is hereby amended and supplemented by adding the following paragraph immediately after the last paragraph of Item 3:

     

    In an underwritten public offering (the “Offering”) on November 20, 2023, Augmedix sold an aggregate of 6,250,000 shares of its Common Stock at a public offering price of $4.00 per share and granted to the underwriters an option to purchase up to an additional 937,500 shares of Common Stock at the public offering price less the underwriting discounts and commissions, which option was exercised in full prior to the closing of the Offering. RedCo II Master Fund, L.P. (“RedCo II”) purchased 750,000 shares of Common Stock in the Offering at the public offering price. The source of funds was working capital of RedCo II.

     

    ITEM 5.Interest in Securities of the Issuer.

     

    Item 5 of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprised of the following: (i) 521,140 shares of Common Stock held by Redmile Capital Fund, L.P., (ii) 161,889 shares of Common Stock held by Redmile Capital Offshore Master Fund, Ltd., (iii) 32,914 shares of Common Stock held by Redmile Strategic Trading Sub, Ltd., (iv) 6,218,238 shares of Common Stock and a warrant to purchase 917,414 shares of Common Stock held by Redmile Private Investments II, L.P., (v) a warrant to purchase 573,384 shares of Common Stock held by RAF, L.P., and (vi) 9,446,146 shares of Common Stock, a Pre-Funded Warrant to purchase 3,125,195 shares of Common Stock, and a Breakeven Warrant to purchase 1,093,799 shares of Common Stock held by RedCo II. Redmile is the investment manager/adviser to each of the private investment vehicles listed in items (i) through (vi) (collectively, the “Redmile Funds”) and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile, Mr. Green and each Redmile Fund each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    Redmile and Mr. Green may also be deemed to beneficially own 2,092 shares of Common Stock issued to Robert Faulkner pursuant to restricted stock units. The restricted stock units were granted to Mr. Faulkner, a managing director of Redmile, in connection with his service as a member of the Board of Directors of the Issuer, and have vested pursuant to the terms of the non-employee director compensation policy. Pursuant to the policies of Redmile, Mr. Faulkner holds the shares of Common Stock issued pursuant to the restricted stock units as a nominee on behalf, and for the sole benefit, of Redmile and its affiliates, and has assigned all economic, pecuniary and voting rights in respect of the shares of Common Stock issued pursuant to the restricted stock units to Redmile. Redmile and Mr. Green each disclaim beneficial ownership of the shares of Common Stock issued pursuant to the restricted stock units, except to the extent of its or his pecuniary interest in the shares subject to the shares of Common Stock issued pursuant to the restricted stock units, if any, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities any purpose.

     

    For purposes of this Schedule 13D with respect to Redmile and Mr. Green, the percent of class was calculated based on: (a) 48,555,216 shares of common stock outstanding as of November 20, 2023, as disclosed in the Issuer’s prospectus supplement filed with the SEC on November 17, 2023 (the “Prospectus Supplement”) and a Form 8-K filed with the SEC on November 20, 2023 (the “Form 8-K”), plus (b) 5,709,792 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants and Breakeven Warrants held by certain of the Redmile Funds that are currently exercisable.

     

     - 6 - 

     

     

    For purposes of this Schedule 13D with respect to Redmile Private Investments II, L.P., the percent of class was calculated based on: (a) 48,555,216 shares of common stock outstanding as of November 20, 2023, as disclosed in the Prospectus Supplement and the Form 8-K, plus (b) 917,414 shares of Common Stock issuable upon the exercise of a warrant that is currently exercisable.

     

    For purposes of this Schedule 13D with respect to RedCo II, the percent of class was calculated based on: (a) 48,555,216 shares of common stock outstanding as of November 20, 2023, as disclosed in the Prospectus Supplement and the Form 8-K, plus (b) 3,125,195 shares of Common Stock issuable upon the exercise of a Pre-Funded Warrant that is currently exercisable, plus (c) 1,093,799 shares of Common Stock issuable upon the exercise of a Breakeven Warrant that is currently exercisable.

     

    (b) For each Reporting Person:

     

    Redmile Group, LLC:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 22,092,211

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 22,092,211

     

    Jeremy C. Green:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 22,092,211

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 22,092,211

     

    Redmile Private Investments II, L.P.:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 7,135,652

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 7,135,652

     

    RedCo II Master Fund, L.P.:

     

    (1) Sole Voting Power: 0

     

    (2) Shared Voting Power: 13,665,140

     

    (3) Sole Dispositive Power: 0

     

    (4) Shared Dispositive Power: 13,665,140

     

     - 7 - 

     

     

    (c) The information in Item 3 above and Item 6 below is incorporated herein by reference.

     

    (d) Not applicable.

     

    (e) Not applicable.

     

    ITEM 6.Contracts, Arrangements, Understandings or Relationship with Respect to the Securities of the Issuer.

     

    Item 6 of the Prior Schedule 13D is hereby amended and supplemented by adding the following paragraph immediately prior to the last paragraph of Item 6:

     

    New Lock-Up Agreements

     

    On November 14, 2023, the Redmile Funds and Robert Faulkner entered into lock-up agreements (the “Lock-Up Agreements”) pursuant to which each agreed, subject to certain exceptions, that during the period commencing upon the date of the lock-up agreements until the date that is nine months after the date of the underwriting agreement, for the Redmile Funds, and 90 days after the date of the underwriting agreement, for Robert Faulkner, the Redmile Funds and Mr. Faulkner would not (i) directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any of their Common Stock (or securities convertible into or exchangeable for shares of Common Stock), or make any demand for or exercise any right with respect to the registration of any of the Common Stock or file any registration statement, (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of their Common Stock, or (iii) publicly announce the intention to do any of the foregoing.

     

    The foregoing summary of the Lock-Up Agreements is not intended to be complete and is qualified in its entirety by reference to the full text of the Lock-Up Agreements, which are filed as Exhibit 99.15 and 99.16 to this Schedule 13D and is incorporated herein by reference.

     

    Item 6 of the Prior Schedule 13D is hereby amended and supplemented by adding the following paragraph immediately prior to the second paragraph of the subsection titled “Breakeven Warrants to Purchase Common Stock”:

     

    Upon the closing of the Offering, the Breakeven Warrants became immediately exercisable on November 20, 2023.

     

    Except as described above, no contracts, arrangements, understandings, or relationships (legal or otherwise) exist between any Reporting Person and any person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies. Except as described above, none of the Reporting Persons is a party to any arrangement whereby securities of the Issuer are pledged or are otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities.

     

    ITEM 7.Material to Be Filed as Exhibits.

     

    The exhibit list in Item 7 of the Prior Schedule 13D is hereby amended and supplemented by adding Exhibit 99.15 and Exhibit 99.16, and the remainder of Item 7 of the Prior Schedule 13D is unchanged and the exhibits listed therein have been previously filed.

     

    Exhibit Number   Description
    Exhibit 99.15   Form of Lock-Up Agreement by and among William Blair & Company and the Redmile Funds
    Exhibit 99.16   Form of Lock-Up Agreement by and between William Blair & Company and Robert Faulkner

     

     

     - 8 - 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 22, 2023 REDMILE GROUP, LLC
       
       
      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Managing Member
       
       
    Dated: November 22, 2023 /s/ Jeremy C. Green
      JEREMY C. Green
       
       
    Dated: November 22, 2023 redmile private investments ii, l.p.
     

     

    By: Redmile Private Investments II (GP), LLC, its general partner

     

    by: redmile group, llc, its managing member 

       
      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Managing Member
       

     

    Dated: November 22, 2023 RedCo II MAster fund, L.P.
     

     

    By: Redco II (GP), LLC, its general partner 

       
      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Managing Member

     

     - 9 - 

     

    Get the next $AUGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AUGX

    DatePrice TargetRatingAnalyst
    7/22/2024Buy → Hold
    Lake Street
    7/22/2024$3.00 → $2.35Buy → Neutral
    B. Riley Securities
    5/14/2024$5.00Buy → Hold
    Maxim Group
    5/14/2024$5.00 → $1.50Outperform → In-line
    Evercore ISI
    4/3/2024$5.50Buy
    B. Riley Securities
    12/15/2023$6.00In-line
    Evercore ISI
    3/7/2022$6.00Buy
    Lake Street
    1/21/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $AUGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ginocchio Paul bought $48,500 worth of shares (10,000 units at $4.85), increasing direct ownership by 8% to 128,000 units (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/27/23 7:00:06 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Redmile Group, Llc bought $6,000,000 worth of shares (1,500,000 units at $4.00) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/22/23 4:15:24 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Augmedix Inc.

      15-12G - Augmedix, Inc. (0001769804) (Filer)

      10/15/24 9:32:28 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:04 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:02 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:01:03 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Faulkner Robert C.

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Director Febbo William J returned $382,070 worth of shares to the company (162,583 units at $2.35), closing all direct ownership in the company (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 1:17:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Augmedix downgraded by Lake Street

      Lake Street downgraded Augmedix from Buy to Hold

      7/22/24 8:25:03 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously

      7/22/24 8:02:58 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by Maxim Group with a new price target

      Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00

      5/14/24 8:17:17 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

      SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu

      8/12/24 4:01:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Augmedix to Join Forces with Commure

      SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price

      7/19/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

      SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog

      5/29/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

      SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr

      4/4/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Financials

    Live finance-specific insights

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

      SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a

      5/13/24 4:03:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Augmedix Inc.

      SC 13G - Augmedix, Inc. (0001769804) (Subject)

      7/29/24 5:23:20 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      7/19/24 7:45:47 PM ET
      $AUGX
      Business Services
      Consumer Discretionary